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Abstract
Background: The importance of the malignant cell environment to its growth and survival is becoming
increasingly apparent, with dynamic cross talk between the neoplastic cell, the leukocyte infiltrate and the stroma.
Most cancers are accompanied by leukocyte infiltration which, contrary to an anticipated immuno-protective role,
could be contributing to tumour development and cancer progression. Epstein-Barr virus (EBV) associated cancers,
including nasopharyngeal carcinoma and Hodgkin’s Disease, show a considerable leukocyte infiltration which
surrounds the neoplastic cells, raising the questions as to what role these cells play in either restricting or
supporting the tumour and what draws the cells into the tumour. In order to begin to address this we have
studied a transgenic model of multistage carcinogenesis with epithelial expression of the EBV primary oncoprotein,
latent membrane protein 1 (LMP1). LMP1 is expressed particularly in the skin, which develops a hyperplastic
pathology soon after birth.
Results: The pathology advances with time leading to erosive dermatitis which is inflamed with a mixed infiltrate
involving activated CD8+ T-cells, CD4+ T-cells including CD4+/CD25+/FoxP3+ Treg cells, mast cells and
neutrophils. Also significant dermal deposition of immunoglobulin-G (IgG) is observed as the pathology advances.
Along with NF-kappaB activation, STAT3, a central factor in inflammation regulation, is activated in the transgenic
tissue. Several inflammatory factors are subsequently upregulated, notably CD30 and its ligand CD153, also
leukocyte trafficking factors including CXCL10, CXCL13, L-selectin and TGFb1, and inflammatory cytokines including
IL-1b, IL-3 and the murine IL-8 analogues CXCL1, CXCL2 and CXCL5-6, amongst others. The crucial role of mature
T- and/or B-lymphocytes in the advancing pathology is demonstrated by their elimination, which precludes mast
cell infiltration and limits the pathology to an early, benign stage.
Conclusions: LMP1 can lead to the activation of several key factors mediating proliferation, angiogenesis and
inflammation in vivo. With the initiation of an inflammatory programme, leukocyte recruitment follows which then
itself contributes to the progressing pathology in these transgenic mice, with a pivotal role for B-and/or T-cells in
the process. The model suggests a basis for the leukocyte infiltrate observed in EBV-associated cancer and its
supporting role, as well as potential points for therapeutic intervention.
Background
There is an increasing body of evidence linking chronic
inflammation and cancer, the complexities of which are
beginning to be unravelled. Inflammation is charac-
terised by the influx of immune cells to a localised site
where they release and respond to factors in a dynamic
state. Under normal circumstances, this occurs to pro-
mote wound repair and combat infection and would be
expected to be temporary, abating when the infection or
injury resolves. However a chronic state of inflammation
can lead to an increased risk of cancer. This link is
exemplified by the association of Helicobacter pylori (H.
pylori) infection (causing chronic inflammation) and
gastric cancer, the second most common malignancy
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ted, including chronic hepatitis B virus (HBV) infection
and hepatocellular carcinoma [3] and the inflammation
induced by chemical irritants (such as smoke or asbes-
tos) with lung cancer.
Almost all cancers are accompanied by leukocyte infil-
tration, the significance of which has recently come
under increasing scrutiny as to whether these cells work
to eradicate the malignant cell, or whether they act to
support it. Various inflammatory cell subsets are now
thought to be able to contribute to tumour progression.
T h ep r e s e n c eo fi n n a t ei m m u n ec e l l ss u c ha sg r a n u l o -
cytes, dendritic cells, macrophages, natural killer cells
and mast cells can functionally contribute to tumour
development via the release of soluble factors which can
mediate tumour-favourable processes including angio-
genesis and tissue remodelling [4]. Additionally, soluble
B-cell-derived factors have been shown to increase
inflammatory cell recruitment and co-ordinately carci-
nogenic progression in a K14.HPV16:E6/E7 transgenic
mouse model of epithelial carcinogenesis [5]. Further-
more, it is becoming increasingly clear that the ability of
tumour cells themselves to secrete and/or respond to
cytokines and chemokines can also provide a survival
advantage [6].
Epstein-Barr virus (EBV) is associated with several
malignancies, most tightly with the epithelial cancer
nasopharyngeal carcinoma (NPC). NPC demonstrates an
intense leukocyte infiltration within the tumour tissue,
mainly composed of T-cells and macrophages and with
the noted expression of interferon (IFN)-g,B L C
(CXCL13), CD40, interleukin-1 (IL-1), several macro-
phage inflammatory and chemoattractant proteins and
in a small number of cases (10%) CD30 [7-10].
The EBV oncogene encoding latent membrane pro-
tein-1 (LMP1) has been shown to upregulate a number
of cytokines and chemokines in various epithelial sys-
tems, including LMP1 transfected epithelial cell lines
and gene expression correlated with LMP1 in NPC
biopsies. These factors include IL-6, IL-1b,I L - 1 a,
CXCR4, RANTES, MCP1, IL-8 and IL-10 [11-17]. Up-
regulation of several factors by LMP1 has been shown
to be mediated through its ability to activate NFBs i g -
nalling. NFBh a sad u a lr o l ei nc a r c i n o g e n e i s ;i t s
expression in potentially malignant cells can prevent cell
death, additionally, it is a prominent mediator of inflam-
mation, regulating the expression of pro-inflammatory
cytokines such as IL-1, IL-6, IL-8 and tumour necrosis
factor a (TNFa) [18,19].
In order to explore molecular and cellular processes in
the very early stages of carcinogenesis, the link with
chronic inflammation and the factors involved, we have
used a transgenic mouse model of multistage epithelial
carcinogenesis wherein LMP1 (of the nasopharyngeal
carcinoma viral strain: LMP1
CAO), is expressed in
epithelia [20]. In this system we have previously shown
that NFB is activated by LMP1 in vivo [21].
I nt h ep r e s e n ts t u d yw eh a v eg o n eo nt oc h a r a c t e r i s e
the inflammatory state in the effected transgenic skin
and explored deregulated expression patterns, particu-
larly those of cytokines and chemokines. The active role
of adaptive immune cells in the inflammatory state in
the model is demonstrated by the genetic removal of B-
and T-cells using a RAG-1 null background, which lim-
its the pathology to an early stage.
Results
Inflammation in the transgenic tissue
L2LMP1
CAO mice have been previously described and
show a hyperplastic phenotype in the skin, which progres-
sively worsens as the mice age. The most striking pheno-
type presents in the hairless skin regions, particularly the
ears of the mice (correlating with the levels of LMP1
transgene expression). This preneoplastic phenotype has
been categorised into five recognisable and predictable
stages, from stage 1 (St1) showing mild hyperplasia with
increased vascularisation to stage 5 (St5) displaying severe
hyperplasia with necrosis and tissue degeneration
(figure 1A, B and detailed in additional file 1 table S1),
which can lead to acanthosis, hyperkeratosis and occa-
sional carcinoma [20]. First, the inflammation status was
assessed in the tissue by examining infiltrating cell types
by immunohistochemistry (IHC). Ear tissue from
L2LMP1
CAO. 1 1 7m i c ew a sa n a l y s e da ts t a g e s2a n d5 ,
representing early and advanced pre-neoplastic pathology
and compared to aged matched controls (C2 and C5
respectively). The tissues were examined for the presence
of mast cells, neutrophils, T-cells, granulocytes and eosi-
nophils. Differences were detected between transgenic and
control tissues in the T-cell, mast cell and neutrophil/
monocyte infiltrate (figure 1). T-cells were present in the
dermis of both the transgenic and control tissue, however
they were increased in number in the transgenic dermis
and were also present in the transgenic epidermis (unlike
the controls) at both early and advanced stages (figure 1,
C-F). Increased numbers of mast cells were evident in the
transgenic tissue compared to controls, localised in the
dermis beneath the epidermal basement membrane whilst
in the controls they showed a more scattered pattern (fig-
ure 1, G-J). Myeloperoxidase staining (used to detect neu-
trophils and monocytes) revealed some weak staining
throughout the dermis of controls and transgenic samples,
however, regions of intense staining in localised areas of
the epidermis were detected in the transgenic tissue only
(figure 1, K-N). In addition in the transgenic stage 4 and 5
tissue, swathes of degenerating neutrophils were apparent
in areas of ulceration and necrosis. These findings are con-
sistent with the pathological diagnosis indicating mixed
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phils and mast cells with areas of degenerate neutrophils
notably in tissue stages 3 to 5.
To characterise the leukocyte subsets within the ear tis-
sue, a cell isolation protocol was used to disassociate the
cells for flow cytometry, avoiding the use of trypsin and
prolonged dispase treatment which can impair surface
marker detection [22]. In reflection of the hyperplastic
pathology, two to three times as many non-transgenic
sibling control (NSC) ears compared to transgenic sam-
ples were required to obtain sufficient cell numbers for
this purpose. In agreement with the IHC analysis, a
greater proportion of CD45
+ leukocytes were present in
t h et r a n s g e n i ce a rt i s s u ec o m p a r e dt ot h ec o n t r o l s
(representative example in figure 2A) with between 60%
and 80% CD45
+ cells (of the FSC/SCC gated population)
in the transgenic samples compared with 2% to 7% in
NSC samples (reverse gating showed that all viable
CD45
+ cells reside within this FSC and SCC gated
population). Of the CD45
+ gated populations 47% were
CD3
+ T cells in the transgenic samples and 54% in the
control samples (bearing in mind the approximately 30
fold smaller CD45
+ population in the controls) (figure
2B). In the transgenic samples, 6.8% (of CD45
+ cells)
were CD3
+NK1.1
+ (indicative of a subset of NKT cells),
the vast majority of the T-cells (CD3
+)b e i n gN K 1 . 1
-
(figure 2B). In the controls 29% (just over half of the T-
cells present) were CD3
+NK1.1
+. Despite the greater
ratio of CD3
+NK1.1
+ to CD3
+NK1.1
- cells in the control
tissue compared to the transgenic, this represents
approximately 8 fold fewer NKT cells per control ear
compared to the transgenic ear. NKT cells can secrete
transforming growth factor b (TGFb), which is a posi-
tive signal for their proliferation yet an inhibitory factor
for their cytotoxic activity. In accordance with this, ele-
vated levels of mature (processed) TGFb1 (figure 2D),
but not b2o rb3( n o ts h o w n )w e r eo b s e r v e di nt h e
transgenic St5 samples. No NK1.1
+CD3
- cell population
(indicative of NK cells) was apparent in either transgenic
or NSC samples (figure 2B). Moreover, elevated Rae-1
levels were observed in St5 samples compared to con-
trols (figure 2D). Rae-1 is a ligand which activates NK
cells (NK1.1
+CD3
-) via the NKG2D receptor, however
sustained elevation of Rae1 results in impaired NK cell
function and a subsequent decrease in anti-tumour
immunosurveillance [23]. Thus we would predict that
the inflamed transgenic tissue environment would be
inhibitory for NKT and NK cytotoxic activities.
Further characterisation of the T-cell subsets revealed
that 7% were positive for CD4 and/or CD8 (of the FSC/
SSC gated population) in the transgenic samples com-
pared to 4.3% in controls (figure 2A). In addition, the
transgenic samples showed a large proportion of leuko-
cytes negative for CD4 and CD8, presumably including
the mast cells and neutrophils noted above. The CD8:CD4
ratio for transgenic compared to NSC was 1.2 and 2.6
(respectively), suggesting a relative increase in the CD4
+
population in the transgenic samples (figure 2A). Co-stain-
ing of the CD8
+ populations revealed that virtually all were
granzyme-B
+ (figure 2C) in both transgenic and control
samples, indicating that the cytotoxic T-cells within the
ear tissue are activated and that this is normal, although
t h e r ea r em o r ei nt h et r a n s g e n i ct i s s u ec o m p a r e dt ot h e
Figure 1 Infiltrating cells in transgenic tissue. Formalin fixed,
tissue sections were immunostained with : A-B: anti-von Willebrand
factor revealing blood vessels (brown stain) shown at original
magnification x10 (see additional file 2, figure S1 for details); C-F:
anti-CD3 to reveal T-cells (brown stain), at x100 (C, D) and x400 (E,
F) original magnification; G-J: astra blue staining to reveal mast cells
(blue) at x10 original magnification (G, H) with indicated areas
enlarged in I and J; K-N: anti-myeloperoxidase to reveal neutrophils
and monocytes (brown staining) at either x100 (K, L) or x400 (M)
original magnification, with a region of the intensely stained
epidermis (boxed in L) enlarged in (N). LMP1
CAO.117 transgenic ear
phenotypic stage 2 and 5 (St2 and St5 respectively) and NSC (C2
and C5) samples were used. The epidermis, e, dermis, d, and
cartilage, c, are indicated. Dashed lines indicate the epidermal
basement membrane.
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Page 3 of 19Figure 2 Characterisation of the T-cell infiltrate. A, B, C: Cell suspensions from transgenic St3/4 (Tg) and control (NSC) ear tissue
(approximately 10
6 cells/sample, each from two transgenic ears or 4 to 6 control ears) were analysed by flow cytometry using fluorescent-
conjugated antibodies. In all cases, the leukocyte populations were first gated by forward and side scatter as shown in the first panel of A. Viable
leukocytes were further gated as the CD45
+(APC)/7-AAD
-(PerCP) population shown in the middle panel of A. Cells were further stained using
antibodies directed to CD4(PE) and CD8(FITC) (A), NK1.1(PE) and CD3(FITC) (B) and CD8(FITC) and Granzyme B(PE) (C); showing proportions of
cells in relevant quadrants or gates. CD4/CD8 proportions in (A) are given as the % of CD45
+/7-AAD
- cells (black) and as the % of the gated
FSC/SSC cells (red). D: Protein was extracted from control (NSC: C5) and transgenic ears (St5). Three biological replicates (40 μg) were western
blotted and probed with anti-TGFb1 (upper panel: 15% gel, precurser dimer: 44kD, mature protein dimer: 25kD, under these reducing conditions:
22 and 12.5kD respectively) or a-Rae1 (lower panel: 12.5% gel, migrates at ~40kD). a-GAPDH was used as a loading control as indicated (37kD).
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+ cells were found to co-stain with CD25
and FoxP3 (not shown). Analysis of the CD4
+ cells
revealed a proportion (approximately 9% of the total CD4
+
population) in the transgenic samples co-staining for both
CD25 and FoxP3, indicative of Treg cells, while no such
population was apparent in controls (figure 3). Thus the
transgenic samples show increased numbers of CD4
+ T-
cells with an increased proportion of Treg cells compared
to controls.
Immunoglobulin deposition in the transgenic tissue
Immunoglobulin deposition is a recognised feature of sev-
eral chronic inflammatory disorders, such as rheumatoid
arthritis and the active role of B-cells in autoimmune
disease is evidenced by a decrease in disease severity fol-
lowing B-cell depletion in patients [24]. Immunoglobulin
deposition and a B-cell role in disease is also proposed for
several carcinomas, including breast and prostate cancer
and was observed experimentally in the skin of human
papillomavirus 16 (HPV16) transgenic mice [25]. In order
to determine if immunoglobulin deposition also occurs in
the L2LMP1
CAO mice, the ear tissues were examined by
western blotting and IHC. Biological replicates of trans-
g e n i ct i s s u ea ts t a g e s1 ,2a n d5a l o n gw i t hc o n t r o l s
revealed heavy and light chain IgG antibody bands in all
samples, these were slightly increased in St2 samples com-
pared to controls but were markedly more intense in the
St5 extracts (figure 4A). By IHC, the IgG deposition was
observed to be pronounced throughout the dermis of the
transgenic tissue and not in controls (figure 4B and addi-
tional file 2 figure S2). In order to assess if B-cells were
infiltrating the tissue (although this is not necessary for
immunoglobulin deposition to occur), sections were
immunostained with antibodies to CD20 and CD19. No
staining was observed in the skin samples using anti-
CD20, however, very sparse positively stained lymphocytes
with plasma cell appearance in the transgenic dermis were
apparent using anti-CD19, while no specific staining could
be detected in controls (figure 4C).
The inflammatory environment in the transgenic tissue
The transgenic tissue clearly shows considerable inflam-
matory cell infiltration. In order to gain a broad over-
view of the status of inflammatory factors in the
transgenic tissue environment, cytokine and chemokine
levels were examined in both serum and ear tissue of
L2LMP1
CAO.117 and NSC mice using a multiplexed
immunodetection array (table 1, the full list tested is
shown in additional file 1 table S2). Serum and ear tis-
s u ef r o mS t 5p h e n o t y p em i c ea n de a rt i s s u ef r o mS t 2
phenotype mice were compared with C5 and C2
(respectively), pooling four samples in each group. Of
the cytokines known to be influenced by LMP1 expres-
sion in other systems, IL-4 and IL-6 showed no differ-
ence between transgenic and NSC in either serum levels
or in the pathological tissue extract (additional file 1
table S2). Similarly, TNFa was not obviously induced in
the transgenic samples, however one of its receptors,
TNFRII, was detected at higher levels in the St2 tissue
sample. The multifunctional factor IL-10 (induced by
LMP1 in B-cells [26,27]), was detected at approximately
2 fold lower levels in the serum (compared to NSC), but
approximately 2 fold higher levels within the affected
tissue. The chemokine IL-8, through binding to the
receptors CXCR1 and CXCR2 recruits and activates
neutrophils, and its induction is associated with LMP1
in NPC [13,28]. Rodents lack a direct homologue of IL-
8, however the chemokines CXCL1/KC, CXCL2/MIP2
Figure 3 Increased Treg cells in the transgenic tissue.C e l l
suspensions from transgenic St3/4 and control (NSC) ear tissue
(approximately 5 × 10
5 cells/sample) were analysed by flow
cytometry using fluorescent-conjugated antibodies. The leukocyte
populations were first gated by forward and side scatter as shown
in figure 2. Cells were stained using antibodies directed to CD4
(FITC), CD25(PE) and FoxP3(APC). CD4
+CD25
+ cells gated in the
upper panel are shown for FoxP3 staining in the middle and lower
panels. The proportions of cells in relevant quadrants or gates are
given.
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Page 5 of 19Figure 4 Immunoglobulin deposition in the transgenic dermis. A: Protein was extracted from control (NSC: C1, C2, C5) and transgenic ears
(St1, St2, St5). Two biological replicates (40 μg) were separated by 10% SDS-PAGE, western blotted and probed with goat a-mouse IgG-HRP. The
immunoglobulin heavy (H) and light (L) chain bands are indicated at 55kD and 25kD respectively. Molecular weight markers are shown (kD). B
and C: Ear tissue sections for transgenic St4 and NSC (C4) were immunostained with goat a-mouse IgG shown at original magnification of x100
(B) and anti-CD19 detecting B-cells at x400 (C).
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Page 6 of 19and CXCL5-6/LIX are regarded as functional analogues
[29]. Like IL-10, KC was detected at approximately 2
fold lower levels in the serum (compared to NSC), but
approximately 2 fold higher levels within St2 tissue.
MIP-2 was observed at 4.2 and 2.8 fold higher levels
(St2 and St5 respectively) in the transgenic tissues and
LIX at 3.7 and 2.2 fold higher levels (respectively), again
without increase in the serum. Thus all three IL-8 mur-
ine analogues were observed at higher levels in the
LMP1 affected transgenic tissue. IL-1b was found at 2
to 3 fold higher levels in the transgenic samples, but not
IL-1a, which was at lower levels in the transgenic tissue.
Of the factors analysed in the array, those showing the
greatest upregulation in the transgenic samples com-
pared to NSC in tissue extracts (and in some cases
serum also) were CD30 and its ligand CD153 (CD30L),
CXCL13 (BLC), CXCL10 (CRG-2 or IP10), CD40, L-
selectin and IL-3. Expression in the tissues of these fac-
tors was explored further by western blotting and IHC.
In some cases the data were ambiguous due to cross-
reactivity detected by the available antisera. However,
clear upregulation in the transgenic St4 and St5 tissue
of CD153 (CD30L), a costimulatory molecule expressed
by activated B- and T-cells, mast cells and macrophages,
was detected (figure 5). No CD153 was detected by wes-
tern blotting in the control tissues (figure 5) and very
little immunohistochemical staining was observed (figure
6 and additional file 2 figure S3). In the transgenic tissue
CD153 was observed in the cytoplasm of infiltrating
inflammatory cells, probably mast cells and fibroblasts
as well as intense staining in vascular endothelial cells,
which was not detected in NSC tissue sections (figure 6).
CD30 was also confirmed as upregulated by western
blotting in St5 extracts (figure 5), but due to antibody
cross reactivity, specific staining could not be determined
in tissue sections. L-selectin is an adhesion molecule
which is usually expressed on the surface of leukocytes
and mediates their migration from the blood stream. By
IHC, L-selectin was observed in the transgenic tissue,
with weak staining in nuclei and cytoplasm of the epider-
mal cells (figure 6 and additional file 2 figure S4). Some
weak staining in the nuclei of control epidermal cells was
also seen, which may reflect non-specific staining. Speci-
fic staining for L-selectin was observed in the transgenic
tissues within mast cells in a clear granular pattern indi-
cative of L-selectin present within the mast cell granules
(figure 6 and additional file 2 figure S4). Rare cells stained
for L-selectin in the NSC tissues. IL-3, a potent growth
promoting cytokine, was observed to be upregulated at
St5 but not St2 by western blotting with none detected in
controls (figure 5). IL-3 immunostaining was detected in
the transgenic tissue in fibroblasts, infiltrating cells and
in vascular endothelial cells, but not in controls (figure 6
a n da d d i t i o n a lf i l e2f i g u r eS 5 ) .C X C L 1 0( o rC R G - 2o r
IP10) is an IFNg responsive chemokine with pleiotropic
affects. Binding to its receptor (CXCR3) can induce
T-cell migration, modulation of adhesion molecule
expression and monocyte and NK cell stimulation.
CXCL10 showed an 11 fold increase in the transgenic
Table 1 Cytokines and chemokines showing greater than
2 fold difference between transgenic and NSC samples
Serum St5/C5 Tissue St2/C2 Tissue St5/C5
cytokine ratio cytokine ratio cytokine ratio
CD30 16.49 CD30L ∞ CD30L ∞
TIMP-1 9.01 CD30 ∞ CD30 ∞
MIP-1g 6.06 CXCL13(BLC) 18.06 CXCL13(BLC) 18.42
CD30L 4.17 CXCL10(CRG-2) 11.86 CXCL10(CRG-2) 11.47
Leptin 3.20 CD40 8.80 MIP-3a 7.09
IL-3Rb 2.62 L-Selectin 8.50 CD40 5.21
Eotaxin 2.48 IL-3 6.11 IL-12P40/P70 5.17
FasLigand 2.27 MIP-2 4.20 IL-3 4.60
XCXL10(CRG-2) 2.19 MIP-3b 3.92 L-Selectin 4.19
RANTES 2.06 sTNF RII 3.83 MIP-3b 3.23
CTACK 2.05 IL-12P40/P70 3.76 IL-2 3.10
IL-3 Rb 3.73 MIP-2 2.84
TARC 0.50 LIX 3.72 CXCL16 2.70
IGFBP-3 0.48 IL-2 3.39 AXL 2.61
MIP-3b 0.46 MIP-3a 3.30 IL-3 Rb 2.30
KC 0.46 TIMP-1 3.14 GCSF 2.28
IL-12p40/p70 0.46 IL-1 b 3.09 VEGF 2.25
IL-13 0.43 IGFBP-5 2.95 LIX 2.23
MIP-3a 0.35 TPO 2.85 IFNg 2.19
IL-17 0.25 IL-13 2.71 GM-CSF 2.18
IFNg 0.23 IL-17 2.69 IL-1 b 2.16
IGFBP-5 0.20 GCSF 2.42
TARC 0.50 VEGF 2.41 IL-1a 0.38
IGFBP-3 0.48 VCAM-1 2.30 IGFBP-6 0.36
MIP-3b 0.46 PF-4 2.19
KC 0.46 KC 2.11
IL-12p40/p70 0.46 AXL 2.10
IL-13 0.43 IL-10 2.10
Leptin R 2.05
GM-CSF 2.04
IFNg 2.00
IGFBP-6 0.37
eotaxin2 0.31
A pool of four samples (from different mice) were used for each sample
assayed by cytokine immunodetection array. Samples were taken from serum
from transgenic mice with St5 ear phenotype and serum from non-transgenic
sibling controls (NSC) (1
st column), transgenic stage 2 ear tissue extracts (St2)
compared with C2 (2
nd column) and transgenic stage 5 ear tissue extracts
(St5) compared with C5 (3
rd column). The mean of the normalised values
obtained for each cytokine was taken and the ratio of transgenic over NSC
determined. All those factors showing greater than two fold difference are
shown. For CD30 and CD30L (CD153), strong signal was detected in the
transgenic and none in the control samples, as such the ratio cannot be
determined (∞).
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Page 7 of 19Figure 5 STAT3 is activated in the transgenic tissues and inflammatory factors induced. Protein was extracted from control (NSC: C2, C5)
and transgenic ears (St2, St5). Three biological replicates (100 μg) were separated by SDS-PAGE and western blotted. A: 10% gel probed with a-
CD153 (migrates at ~44kD); B: 10% gel probed with anti-CD30 (migrates at 120kD), note the non-specific bands in two C2 samples due to
relatively high loading, with no CD30 specific band; C: 15% gel probed with anti-CXCL10 (migrates at 10kD); D: 15% gel probed with anti-IL-3
(migrates at 15kD); E: 10% gel probed sequentially with anti-phospho-ser727-STAT3 (migrates at 89kD) then anti-total-STAT3 (a isoform migrates
at 86kD, b isoform migrates at 79kD). Detection of GAPDH was used as a loading control (37kD) shown below each panel.
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Page 8 of 19tissue compared to controls by the array and was con-
firmed to be upregulated in the transgenic St5 tissue by
western analysis (figure 5).
Several members of the macrophage inflammatory
protein group showed considerable upregulation in the
transgenic samples by the array analysis, specifically
macrophage inflammatory protein-1g (MIP-1g)i nt h e
serum (which has been confirmed by ELISA - not
shown), MIP2 (CXCL2, discussed above), MIP-3a and
MIP-3b in the tissues. Additionally IFNg, found induced
in NPC tissues, was detected at approximately 2 to 3
fold higher levels in the St2 and St5 tissues, with
reduced levels in serum compared to controls, a pattern
also observed with IL-10 and the murine IL-8 analogues.
The cytokines IL-12 (proposed to be induced by LMP1
in B-cells [30]), IL-2, IL-3 (and receptor IL-3Rb) and the
pro-inflammatory IL-1b were detected at higher levels
in St2 and St5 tissues than controls. The angiogenic
factor vascular endothelial growth factor (VEGF) was
also detected at higher levels in the tissue samples (2x)
and was previously observed to be induced in the trans-
genic samples by western blotting [20]. Members of the
insulin-like growth factor binding protein group
(IGFBP) were amongst the few factors showing reduced
levels in the transgenic serum and tissues by the array
analysis (table 1 and additional file 1 table S2).
It is becoming increasingly apparent that signal trans-
ducer and activator of transcription-3 (STAT3) is a
seminal factor in inflammatory processes. Persistent
activation of STAT3 has been linked with tumour-asso-
ciated inflammation and suppression of anti-tumour
immunity [31]. STAT3 has two isoforms (a and b)
which show differences in function [32]. STAT3 expres-
sion and activation (by phosphorylation at serine 727,
which affects DNA binding and transcriptional activity)
were examined in the transgenic tissues compared to
Figure 6 Expression of CD153, L-selectin and IL-3 within the transgenic tissue.R e p r e s e n t a t i v ef o r m a l i nf i x e d ,t i s s u es e c t i o n sf r o m
LMP1
CAO.117 transgenic ear phenotypic St4 and NSC (C4) were immunostained with anti-CD153, anti-L-selectin and anti-IL-3 (brown stain) as
indicated. Original magnification x200 is shown in the upper two panels with x400 of the St4 sections in the lower panel (further micrographs
are shown in the supplementary information). Some example features are identified: b = blood vessels, c = cartilage, d = dermis, e = epidermis,
f = positive staining in fibroblasts, g = positive staining in vascular endothelial cells, m = granular positive staining in the cytoplasm of mast cells.
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form expressed in transgenic and control ear tissues. A
lower level of STAT3b was detected in the transgenic
and control young mice (St2 and control), however in
the older mice (St5 at 6 months), the b form was
reduced in controls, but not in transgenic samples.
Increased levels of activated (ser-727-phosporylated)
STAT3a was detected in the transgenic St2 samples
compared to controls, but at the later St5 there were
equivalent levels to controls (figure 5D). Interestingly, a
doublet of phosphorylated STAT3 was observed in all
control samples, each band of the doublet at roughly
equal intensity, while only the upper band (STAT3a)
was observed in the transgenic samples. The lower
phosphorylated band of the doublet, not observed in the
transgenic samples, is presumably the phosphorylated
STAT3b isoform. Thus STAT3 is activated in the trans-
genic samples compared to controls at an early stage
(St2) during the onset of the inflammatory pathology
and the two isoforms are differentially regulated at the
later stages.
The contribution of B- and T-cells to the phenotype
We next explored if adaptive immune cells present in
the phenotypic tissue contribute to the LMP1 induced
pathology. L2LMP1
CAO.117 mice were bred into a
RAG1-null background (lacking mature B-cells, T-cells
and NKT-cells). LMP1/RAG1-null (n = 11) were com-
pared to LMP1/RAG1-het (n = 18) over a 6 month per-
iod from birth (figure 7). The ear phenotype was staged
1-5 on a weekly basis. Within the time scale of the
study, the majority of LMP1/RAG1-het mice reached at
least St3 phenotype (17/18) and most reached St4 (14/
18) with a proportion reaching St5 (5/18) (figure 7), fol-
lowing a phenotypic progression indistinguishable from
the LMP1 mice in a wild type background (not shown).
In contrast, none of the LMP1/RAG1-null mice passed
St2 of the phenotype (epithelial hyperplasia) with 2/11
animals failing to advance beyond St1. The difference
over time to develop each stage of the phenotype was
highly significant between the two populations (St2: p =
0.009; St3: p < 0.0001, St4: p = 0.0033). Histopathology
of tissues at the end of the study period (6 months) con-
firmed the staged observations, revealing a mild hyper-
plasia in the LMP1/RAG1-null St2 tissues compared to
the typical St4 pathology in the LMP1/RAG1-het St4
tissue (figure 7C). Analysis of T-cell infiltrate shows the
presence of T-cells in the LMP1/RAG1-het tissue and
confirms the absence of T-cells in the LMP1/RAG1-null
tissue (figure 8A, B). Similarly, the degree of mast cell
infiltration in the LMP1/RAG1-null tissue is less than
that observed in the LMP1/RAG1-het littermates (the
former is similar to LMP1-St2 ears in a wild type back-
ground), whilst the LMP1/RAG1-het tissue displays
mast cells localised beneath the dermal/epidermal
basement membrane as observed for St4 and St5
L2LMP1.117 in a wild type background (Figure 8C,
D). Lastly, the number of dermal neutrophils/mono-
cytes is also fewer in the LMP1/RAG1-null compared
to the LMP1/RAG1-het tissue. Thus, the presence of
B- and/or T-cells is required for the phenotype to
advance from the initial state of hyperplasia to severe,
inflamed hyperplasia with necrosis and tissue degen-
eration from which keratoacanthoma and other neo-
plasms arise.
Discussion
Extensive leukocyte infiltration is a feature of several
cancers, including the EBV associated malignancies
NPC, Hodgkin’s Disease (HD) and gastric cancer. We
have used a model of epithelial carcinogeneisis, trans-
genic mice expressing the primary oncogene of EBV,
LMP1, to explore the inflammatory processes prior to
neoplasia. The ears of the L2LMP1
CAO mice (the tissue
where LMP1 is expressed at the highest level) and to a
lesser extent other regions of body skin develop a pre-
neoplastic pathology of hyperplasia with increased vas-
cularisation, progressing to acanthosis, hyperkeratosis,
parakeratosis and erosive or ulcerative dermatitis, which
can lead to the development of keratoacanthoma, papil-
loma and ultimately carcinoma. Examination of the pre-
neoplastic stages has revealed that the tissue is inflamed,
with infiltrates of T-cells, mast cells and neutrophils,
that occasional plasma cells are observed and IgG is
deposited in the dermis and that several cytokines and
chemokines involved in inflammation are induced. The
increased numbers of T-cells in the transgenic tissue
include both CD8
+ and CD4
+ cells, with a bias towards
the latter as well as the induction of CD4
+/CD25
+/FoxP3
+ Treg cells.
We have previously reported the deregulation of pro-
teins involved in hyperproliferation, inflammation,
metastasis, angiogenesis and oxidative stress in the
LMP1 expressing transgenic tissue [20,21,33] and now
show the induction of further inflammatory chemokines
and cytokines. The consequence of this LMP1-initiated
expression programme in vivo is a hyperplastic tissue
which is chronically inflamed and is predisposed to car-
cinogenesis. Several genes found to be up or down-regu-
lated in LMP1 expressing tumour tissues and in the
L2LMP1
CAO transgenic model, will result from a cas-
cade of events due to the multiple cell interactions
within a complex tissue, initiated by LMP1 but not
necessarily direct targets of LMP1 signalling. In addition,
gene expression changes within the tissue could origi-
nate from either the neoplastic cell, the leukocyte infil-
trate or the stroma and thus would not necessarily be
detected in a cultured clonal cell line. Nevertheless,
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Page 10 of 19Figure 7 Phenotype limitation in a B/T-cell deficient background. A and B: Two cohorts of LMP1 transgenic mice, in either a RAG1 null (-/-),
n = 11 (A) or RAG1 heterozygote, n = 18 (+/-) (B) background were monitored weekly (from 4-29 weeks old). The phenotypic stage of the ears
of each mouse was recorded. Two dimensional area plots represent the percentage of mice at each ear stage (y axis) at weekly intervals (x axis).
C: H&E staining of tissue sections from the ears of RAG1 null or RAG1 heterozygote mice in the presence or absence of the L2LMP1
CAO
transgene, as indicated. Original magnification: x100. Note, mice in this study were all 75% C57Bl/6/25% FVB strain.
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involved in proliferation and inflammation in the
SCC12F carcinoma cell line [16]. Upregulation of IL-1b
and CD40 have been found in common in the SCC12F
cell line system [16], in NPC tissues [7] and in our
transgenic model. Additional proteins found to be upre-
gulated in EBV associated disease, such as CXCL13 in
NPC and CD30 in Hodgkin’s disease (HD) (and in some
NPC), were also detected at high levels in the transgenic
tissue, but not in the SCC12F cell line system, suggest-
ing that these may result from in vivo interactions.
Therefore transgenic mouse epithelial expression of
LMP1 represents a valuable model to study the LMP1
induced deregulated cellular expression programme and
Figure 8 Reduced inflammation in a RAG1 null background. Immunohistochemical analyses of ear tissue sections from LMP1
CAO.117
transgenic mice in a RAG1-null background (LMP1.RAG1
(-/-)) compared to RAG1 heterozyous background (LMP1.RAG1
(+/-) Formalin fixed, tissue
sections were immunostained with: A, B: anti-CD3 to reveal T-cells (brown stain), at original magnification: x200; C, D: astra blue staining to
reveal mast cells (blue) at original magnification: x100 E, F: anti-myeloperoxidase to reveal neutrophils and monocytes (brown stain) at original
magnification: x100.
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and the tissue as a whole.
A key advantage of this in vivo model is that we can
examine the sequential changes through time as the
pathology develops from pre-neoplastic stages through to
malignancy. Expression changes noted in the very early
stages in young mice (St1 and St2) may result directly
from LMP1 activation of target signalling pathways and
be causal in the phenoytpe. Conversely, expression differ-
ences noted in the later stages only (St4, St5, papilloma
and carcinoma), are likely to result from the conse-
quences of the earlier altered expression programmes,
such as the infiltration of inflammatory cells, and act to
compound the phenotype. We previously found that
TGFa and other epidermal growth factor (EGFR) ligands
(including HB-EGF and EPR) were consistently upregu-
lated in the transgenic tissue from the earliest stages,
indicating that induction of these ligands result directly
from LMP1 expression [20,21], furthermore increased
serum TGFa has been correlated with poor prognosis in
NPC patients [34]. EGFR is a known target of LMP1
through NF-B activation [35,36] and we found that
EGFR was induced (and NF-B activated) by LMP1 in
the transgenic tissue, but subject to homeostatic modula-
tion in vivo,m e d i a t e di np a r tt h r o u g hT G F a [21].
STAT3, like NF-B, is a key regulator of inflammatory
processes and frequently activated in cancer [31]. It has
been proposed that LMP1 induction of EGFR is mediated
by STAT3 through Bcl-3 in conjunction with NF-B [37].
In the reciprocal process, signalling through EGFR can
activate STAT3 [38], producing a feed forward loop
between these factors. Moreover, nuclear EGFR and
STAT3 physically interact to activate gene expression
[39]. Increased STAT3 activation by phosphorylation was
detected in the tissues of young transgenic mice (St2)
compared to controls, suggesting an early role in the phe-
notype. By the later St5, phosphorylated STAT3a levels
were similar to controls, at a point when EGFR levels are
greatly reduced in the transgenic tissue [21], potentially
reflecting a synergy between these factors in vivo.H o w -
ever in the St5 samples there are clearly differences in
the regulation of STAT3 compared to controls. Higher
levels of STAT3b a r ee v i d e n ti nt h et r a n s g e n i cS t 5s a m -
ples, while in the controls the anti-phospho-ser727 anti-
body reveals a STAT3 doublet not apparent in the
transgenic tissues. The STAT3b isoform results from a
splice variation and lacks the C-terminal transactivation
domain present in STAT3a and has been found to have
different nuclear retention properties from STAT3a and
different function [32,40]. The relevance of the differen-
tially regulated isoforms of STAT3 in the transgenic tis-
sue is at present unknown.
NF-B and STAT3 regulate numerous genes involved
in inflammation and growth transformation and their
persistent activation is observed in many cancers [31].
In this transgenic model, multiple inflammatory chemo-
kines and cytokines were found to be deregulated and
of particular note, CD30, a costimulatory molecule
belonging to the TNFR family and its ligand CD153
were found to be induced. Several chronic inflammatory
disorders, including psoriasis and atopic dermatitis, are
associated with increased numbers of mast cells as well
as upregulation of CD30 and CD153 [41]. CD30 is also
expressed on endothelial cells in a large proportion of
neoplastic and reactive vascular lesions [42] including
the neoplastic Reed-Sternberg cells of HD and anaplastic
large cell lymphoma (ALCL), and high serum levels of
CD30 are correlated with poor prognosis in HD patients
[43]. Expression of CD30 in normal tissues is limited,
making it a good therapeutic target, indeed anti-CD30
treatment has been shown to be efficacious in ALCL
[44] and elimination of CD30 was shown to significantly
reduce airway inflammation in a model for allergic
asthma [45]. CD30 expression by endothelial cells has
also been seen in the inflammatory condition of scleros-
ing angiomatoid nodular transforming (SANT), which
can be EBV positive [46]. The ligand, CD153, is overex-
pressed in a variety of skin inflammations and in the
m a s tc e l l sw i t h i nH Dt u m o u r s[ 4 7 ] ,a sw e l la ss h o w i n g
increased levels (along with increased mast cells) in the
synovium and serum of rheumatoid arthritis patients
[48]. CD30 has been shown to lead to degranulation
independent secretion of chemokines such as MIP-1
from mast cells [41]. The high levels of both CD153 and
CD30 detected in the transgenic ear tissue, as well as
members of the MIP family suggest that this could be
one mechanism of release of mast cell factors here.
CD30 and CD153 showed considerable upregulation
particularly in the later stages (St4 and St5) of the trans-
genic tissue with no expression detected in controls.
CD30 expression is thought to be regulated in part
through the promoter AP1 site and particularly via JunB
which is deregulated in several malignancies [49,50]. We
have previously shown increased AP1 activity in the
transgenic ear tissue and marked upregulation of JunB,
which could underlie induction of CD30 in this model
[21]. However, it is not clear if these activities are pre-
sent in the same cellular compartment as the induced
CD30 and CD153 expression, with CD153 detected pri-
marily in the vascular endothelial cells and mast cells.
Moreover, consistent JunB induction from an early age
and phenotypic stage was observed suggesting direct
upregulation by LMP1, while CD30 and CD153 induc-
tion was detected at the later stages in mice usually
older than 4 months, indicating this upregulation fol-
lows a cascade of events in vivo.
Strong L-selectin staining was seen in the granules of
mast cells with a weak staining in the epidermis (both
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involved in leukocyte trafficking and implicated in a
number of inflammatory disorders. Mast cell precursors
are thought to be recruited from the blood, migrating
from the bone marrow to the tissue, where they differ-
entiate and mature [51]. L-selectin deficiency has been
found to inhibit mast cell recruitment to a repeatedly
antigen stimulated skin site [52]. Thus the expression of
L-selectin in the mast cells of the transgenic skin may
be required for the recruitment of the mast cells to the
site and blockade of L-selectin could inhibit this and
potentially alleviate the pathology. Recently selectins
have become increasingly viable targets in the therapy of
inflammatory diseases [53].
IL-3, produced by activated T-cells, monocytes and
stromal cells can induce the proliferation, maturation
and survival of several hematopoietic cell types, includ-
ing mast cells [54,55]. It has overlapping functions with
GM-CSF and both of these factors were indicated to be
increased in the transgenic tissues by array analysis. IL-3
induction in the transgenic tissue was confirmed by
western blotting suggesting that the transgenic tissue is
supportive for mast cell survival.
CXCL13 (BCL) was notably upregulated in the trans-
genic tissue samples from the array data. CXCL13 is
implicated in the trafficking of B-cells into tissues and
has been shown to be upregulated in NPC biopsies, as
has CD40 [7], also found upregulated in the transgenic
samples. CD40 is a costimulatory protein for antigen
presenting cells, particularly B-cells and macrophages,
furthermore CD40/CD40L signalling is required for T-
cell dependent B-cell differentiation and antibody
secretion.
CXCL10 (CRG2 or IP10), a ligand for CXCR3, regu-
lates leukocyte trafficking. It is a chemokine that is asso-
ciated with tissue damage and necrosis [56] and its over-
expression has been observed in several autoimmune
and inflammatory conditions, including psoriasis [57,58].
CXCL10 is induced in several cell types by IFNg (which
was detected at increased levels in the transgenic tissue)
and in turn attracts Th1 cells to generate a positive
feedback loop [59]. CXCL10 was upregulated in the
transgenic tissue. Although from the array data induc-
tion was seen at both St2 and St5, by western, clear
upregulation was only detected in the latter stage.
IL-1 is an important mediator of inflammation acting
as an activator of T- and B-cells and NK cells [60]. IL-
1 is overexpressed in psoriatic skin [61] and induces
hyperplastic epidermal lesions in transgenic mice
[62,63], with several similarities to the phenotype
observed in our LMP1 transgenic mice. IL-1 is also
implicated in other inflammatory disorders such as
rheumatoid arthritis, inflammatory bowel disease and
atherosclerosis and has been shown to promote auto-
antibody production in the murine lupus model MRL/
lpr mice [64]. We observed increased levels of IL-1b,
but decreased levels of IL-1a in the LMP1 transgenic
skin. IL-1 has been shown to stimulate the production
of IL-2 but inhibit IL-4 expression, consistent with
this, IL-2 was found at higher levels in the transgenic
skin samples (>3 fold) while IL-4 was not induced.
Furthermore, targets of IL-1 were also found to be
induced: GM-CSF was increase 2 fold and S100A9 was
previously found to be considerably elevated in a pro-
teomic analysis [33].
IL-8 (or CXCL8) binds to the CXCR1 and CXCR2
receptors on neutrophils, inducing their recruitment and
activation and has been detected at elevated levels in a
proportion of NPC, HD and BL samples [13,65,66]. All
three rodent analogues, CXCL1/KC, CXCL2/MIP2 and
CXCL5-6/LIX were observed at higher levels in the
transgenic tissue, particularly MIP2 which can recruit
both neutrophils and lymphocytes in vivo [67].
TGFb1 is the most potent known neutrophil chemoat-
tractant; large numbers of neutrophils were seen in the
stage 4 and 5 tissues in which increased TGFb1 levels
were detected, particularly around the necrotic areas.
TGFb1 induction might also be expected to inhibit the
proliferation and activity of mature helper and cyotoxic
T-cells as well as NK cells. Also, TGFb1 augments regu-
latory type T-cells to dampen immunosurveillance,
including NKT cells [68,69]. Additionally, TGFb1i n
conjunction with IL-2 (also found at higher levels in the
transgenic tissue as noted above), induces FoxP3
+ Treg
cells [70], which were found in the transgenic tissue but
not in controls. Treg cells secrete IL-10 which was
found at higher levels in the transgenic tissue, which
would contribute to immunosuppresion [71]. LMP1 has
been found to exert immunosuppressive effects [72,73],
which would be compounded in the transgenic tissue by
the release of TGFb1. Moreover, the sustained induction
of Rae-1 would impair the actions of NK cells in immu-
nosurveillance. Therefore the transgenic tissue environ-
ment is one of sustained inflammation with predicted
suppression of cytotoxic activites.
Several induced factors in the transgenic skin recruit
or activate B- or T-cells and indeed T-cell infiltration
was evident as well as a significant IgG deposition. The
relevance of these cells in the pathology was demon-
strated by their genetic deletion in RAG1 null mice. The
inflamed state and degree of hyperplasia of the trans-
genic tissue was profoundly limited in the absence of B-
and T-cells. In the RAG1-null background, the LMP1
induced phenotype remained at a stage of mild hyper-
plasia (described here as St2), with a failure to recruit
the innate immune cells seen in a wild type background.
Thus B- and/or T-cells are necessary mediators for the
progression of the phenotype. Using an HPV16:E6/E7
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soluble B-cell-derived or induced factors were capable of
partially restoring the carcinogenic skin phenotype in a
B-cell/T-cell (RAG1) deficient background. If the simi-
larity between the models extends to this finding then
the IgG deposition noted here may be a critical media-
tor in the progression of the LMP1 induced phenotype.
We hypothesize that the role of B-cells in the carcino-
genic progression of this model lies in immunoglobulin
production, which is deposited in the tissue. The role of
the T-cells is likely to be multifold: in providing B-cell
help and in secreting certain cytokines, such as IL-3
which then goes on to induce and support several
hematopoietic cell types, including mast cells; but also
in modulating the environment through the suppressive
activity of Treg cells and their secretion of IL-10 and
TGFb1. The subsequent recruitment of mast cells con-
tributes to the cascade of events leading to chronic
inflammation.
O fn o t e ,i nt h i sa n a l y s i sw eh a v ec o m p a r e dt h e
inflamed, hyperplastic, but pre-neoplastic transgenic tis-
sue with controls; as such, some factors noted to be
affected by LMP1 in human tumour samples but not
observed here (such as IL-4 and IL-6), could reflect our
focus on incipient neoplasia in this study. Also, some
observations from our study are likely to be indicative of
skin-specific responses, possibly different in type to
those seen in the mucosal epithelium of NPC. In parti-
cular, observations not noted in EBV-associated disease,
but found in common with the transgenic carcinoma
model expressing E6 and E7 of human papilloma virus
(HPV)-16 in the skin [5], may reflect a tissue-specific
programme. In this respect, it is becoming apparent that
different tissues or organs initially recruit different
immune cell subsets. Recruitment of B-cells or B-cell
factors can be a feature of skin, breast and pancreatic
tumours [25], while tumours of other organs might pre-
ferentially recruit T-cell support at an early phase. Thus
(as with the HPV16:E6/E7 model), the relevance of B-
cells and/or T-cells to the pathology probably reflects
both the actions of the initiating oncogene (LMP1 in
this case) as an inducer of proliferation and inflamma-
tion, as well as the tissue under study in the model, in
this case the skin. It can be hypothesized that, when
expressed in a different tissue, LMP1 will lead to inflam-
matory cell recruitment, but possibly with an altered
leukocyte constitution reflecting the tissue type.
Conclusions
In this model, we have shown that transgenic expression
of an oncogene of EBV, LMP1, induces changes in the
levels of numerous proteins involved hyperproliferation,
oxidative stress, angiogenesis, metastasis and inflamma-
tion [20,21,33]. Here we have identified changes in the
levels of several key cytokines and chemokines involved
in inflammation and shown that the tissues are
inflamed. The importance of the B-cell and/or T-cell
infiltrate is demonstrated through its elimination, which
limits the pathology in these mice to an early stage of
benign hyperplasia.
The developing pathology in this model presents a
number of points for potential therapeutic intervention.
These could be applied where relevant both to LMP1
expressing EBV associated carcinomas, as well as skin
tumours and conditions that show a similar pathology.
A hypothesis of the sequential events can be proposed
as follows: expression of LMP1 in the epidermis leads to
the activation of multiple signalling pathways and the
deregulation of several causal factors in proliferation,
angiogenesis and inflammation; which we observe in the
young mice with tissue pathology of St1 and St2. Factors
upregulated or activated include EGFR and its ligands,
V E G F ,A P 1 ,N F - B [20,21] and STAT3, and the
immediate pathology is one of hyperplasia and increased
vascularisation. Subsequently, B-cells and T-cells are
recruited, possibly through the induction of trafficking
f a c t o r ss u c ha sC X C L 1 3a n dC X C L 1 0 ,a n di m m u n o g l o -
bulins are deposited in the tissue. This leads to mast
cell maturation and recruitment, possibly mediated by
IL-3 and L-selectin. Deposited IgG and CD30 and
CD153 may then promote the release of further factors
from the mast cells. The consequences of this cascade
of events is the chronically inflamed tissue denoted here
as St5, from which neoplastic lesions can arise. Under
this hypothesized scheme, CXCL10 and CXCL13, B-cell
and Ig deposition, L-selectin and CD30/CD153 [47]
could represent candidate target points in the therapy of
LMP1-expressing carcinomas, as well as more generally
skin carcinomas and certain inflammatory conditions,
such as atopic dermatitis showing similar pathological
features.
Methods
Transgenic mice
L2LMP1
CAO (line 117 and line 105B) transgenic mice in
a >99% FVB background were used in these studies
[20]. The line 117 mice were cross-bred with recombi-
nase activating gene-1 null (RAG1
-/-) mice maintained
in a C57Bl/6 background [74]. F1 LMP1/RAG1
+/- males
were back-crossed to RAG1
-/- females to produce a
cohort of offspring with RAG1 heterozygote and null
genotypes, thereby ensuring consistency in mouse age,
strain and environmental conditions. The ear phenotype
was staged 1-5 for a cohort of 43 mice every one to two
weeks for ≥180 days. Statistical comparison was made
by Kaplain-Meier curve plots of development of pheno-
typic stage over time. All female mice (LMP1 negative
due to Y chromosomal transgene insert) displayed no
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under UK Home Office license and the research has
complied with Home Office and institutional guidelines
and policies. Tissue samples were frozen in liquid N2
and stored at -70°C for sample extraction or formalin
fixed at 4°C for immunohistochemical analyses. Serum
was isolated by allowing blood to clot overnight, centri-
fuging at 14,000 g for 10min and the supernatant was
stored at -70°C.
Immunohistochemistry
Formalin-fixed paraffin embedded (FFPE) tissues were
s e c t i o n e da t2μm for hematoxylin and eosin (H&E)
staining and IHC. Washed H&E was used to detect eosi-
nophils. Astra blue (revealing mast cells) stained sec-
tions were counter-stained with safranin. Antibodies
were investigated against FFPE tissue using a two-step
IHC technique. Epitope retrieval was achieved using a
microwave pressure cooker (850 W) in 10 mM sodium
citrate pH6 buffer. Sections were stained using an EnVi-
sion+ system a-rabbit HRP kit (Dakocytomation,
K4010) as per manufacturer’s instructions. Following
staining, all sections were washed in H2O, counter-
stained with Gill’s hematoxylin, differentiated in 1% acid
alcohol then the nuclei blued in Scott’s tap water substi-
tute. IHC antibodies were directed to: CD3 (A0452)
used at a dilution of 1:100; myeloperoxidase (A0398)
1:2000, lysozyme (A0099) (Dakocytomation) 1:1000,
CD19 (ebioscience) 1:30, von Willebrand factor (Abcam)
1:750, CD153 (Biolgened) 1:500, IL-3 (Santacruz) 1:500,
L-selectin (antibodies online) 1:50. Images were cap-
tured using a Zeiss Axioskop 2 microscope and KS300i
software (imaging associates).
Isolation of haematopoetic cells from ear tissue and flow
cytometry
Ears were collected from line 117 St3 or St4 mice and
negative controls (using two to three times as many
controls to obtain sufficient cell numbers). Following
optimisation (additional file 1 figures S6, S7 and table
S 3 ) ,t h et i s s u ew a sm i n c e dw i t hab l a d ei nP B S( 2m l /
ear), then incubated in the presenene of collegenase II
and collegenase IV (10 mg/ml), 0.5 mg/ml DNase I with
3m MC a C l 2 at 37°C for 30 mins. At 30 mins, dispase
(final concentration 0.5%) was added and the samples
were further incubated for 15 mins. Two volumes
DMEM containing 10% FBS were then added and the
cells passed through a 30 μm filter (Miltenyi). Cells
were washed (194 × g, 5 min) and resuspended at 2.5 ×
10
7 cells/ml in PBS/1% FBS. Isolated cells for analysis by
flow cytometry were pre-incubated by adding goat
serum to 10%, for 10 mins, washed and resuspended in
PBS/1%FBS. Cells (at least 10
6/sample) were stained
with FITC, PE, PerCP or APC conjugated antibodies
(eBioscience) directed to: CD45, CD3, CD4, CD8,
NK1.1, for 20 mins at 4°C. 7-AAD was used as a live/
dead cell discriminator. Intracellular staining for FoxP3
and Granzyme B was performed according to manufac-
turers guidelines. Briefly, cells were stained with antibo-
dies against CD4 or CD8, and CD25 (for FoxP3) or CD8
(for Granzyme B). The cells were then fixed by incubat-
ing with fixative solution (eBioscience) for 20 mins at 4°
C. The cells were washed twice with permeablization
buffer (eBioscience) and incubated with anti FoxP3 or
anti Granzyme B for 30 mins at 4°C in permeabilization
buffer. Finally samples were washed in PBS/1%FBS and
analysed using a flow cytometer (BD FACSAria or
FACSCalibur) and FlowJo (9.1) software.
Western blotting
Proteins were extracted in RIPA buffer and were sepa-
rated (40-200 μg per track) by SDS-PAGE (7.5%, 10% or
15%), with blotting and blot-washing performed as pre-
viously described [75]. For probing, the blots were incu-
bated in 5% non-fat milk PBS 0.1% (v/v) Tween 20 with
the appropriate anti-sera dilution. Antibodies (with dilu-
tions) used were directed to: TGFb (Abcam) 1:2000,
Rae-1 (R&D Systems) 1:1000, CD30 (Santacruz) 1:1000,
phospho-ser727-STAT3 and total-STAT3 (Cell signal-
ling) 1:1000, GAPDH (Santacruz) 1:1000, and antibodies
as above under IHC but at a dilution of 1:1000; followed
by the appropriate 1:4000 goat anti-rabbit, goat anti-
mouse or donkey anti-goat IgG HRP-conjugates (Santa-
cruz). Detection was performed by enhanced chemilumi-
nescence (liteAblot kit, Euroclone).
Cytokine array [Raybio
R Mouse Cytokine Antibody Array 3
(#AAM-CYT-3)]
Serum or tissue protein extracts were pooled and
assayed according to the manufacturers protocol. Pro-
teins were extracted from tissues using the supplied lysis
buffer, supplemented with 1 mM PMSF and protease
inhibitor cocktail (Sigma:100 mM benzamidine, 200 mg/
ml leupeptin, 200 mg/ml pepsatin A), on ice for 15 min,
clarified by centrifugation (10 min, 4°C 16,000 g) then
stored in aliquots at -70°C. After blocking (1hr at room
temp.) the membranes were incubated with 1.2 ml of
sample (1:10 dilution of serum or 350 μgt i s s u ee x t r a c t
in supplied diluent) at 4°C o/n. The membranes were
then washed 3 × 5 min with 2 ml wash buffer I at RT,
t h e n2×5m i nw i t h2m lo fw a s hb u f f e rI Ia tR T .T h e
detection antibody cocktail (biotin-conjugated) was
diluted in 2 ml of blocking buffer and 1 ml was added
to each of two membranes which were then incubated
at 4°C o/n. Following incubation the membranes were
washed as before and then 1 ml of HRP-conjugated
streptavidin at 1:1000 dilution was added to each mem-
brane and incubated for 2 hrs at RT, then washed as
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Page 16 of 19above. Antigens were visualised using the supplied lumi-
nol system and signal intensities quantified using Mac-
BAS V2.2 software with scanned images.
Additional material
Additional file 1: Supplementary information. This file contains tables
S1, S2 and S3 along with the optimisation protocol for obtaining cell
suspensions from ear tissue, with figures S6 and S7.
Additional file 2: Supplementary information. This file contains figures
S1 to S5.
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